|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pathological findings and physiological functions of amylin have led to the introduction of pramlintide, an amylin analog, for the treatment of diabetes.
|
30919775 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Islet amyloid polypeptide (IAPP<sub>1-37</sub>) or amylin is implicated in the aetiology of diabetes.
|
30466917 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These breakthroughs include, for example, the direct implication of IAP in intestinal tight junction integrity and barrier function maintenance; chronic intestinal challenge with low concentrations of Salmonella generating long-lasting depletion of IAP and increased susceptibility to inflammation; the suggestion that genetic mutations in the IAP gene in humans contribute to some forms of chronic inflammatory diseases and loss of functional IAP along the gut and in stools; stool IAP as an early biomarker of incipient diabetes in humans; and omega-3 fatty acids as direct inducers of IAP in intestinal tissue.
|
31086953 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A better understanding of how β-cell processing of PI and proIAPP, as well as α-cell processing of proglucagon, are impacted by genetic susceptibility and in the face of diabetogenic stresses, may lead to new therapeutic approaches for improving islet function in diabetes.
|
30230179 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we focus on islet amyloid polypeptide (IAPP) mediated loss-of-insulin secreting cells in patients with diabetes.
|
29615609 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used amylin knockout (AKO) mice intravenously infused with either human amylin (i.e, the aggregated form) or non-amyloidogenic (i.e., monomeric) rodent amylin to test the hypothesis that aggregated amylin accumulates in the heart in the absence of diabetes.
|
29066284 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, many agents targeting the CGRP system are in clinical trials, and pramlintide, an amylin analogue, is an approved therapy for insulin-requiring diabetes.
|
29059473 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small molecules, including β-sheet breaker peptides, chemical chaperones, and foldamers, inhibit and disaggregate amyloid formed by human amylin, suggesting the possible use of these small molecules in the treatment of diabetes.
|
30082607 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pancreatic islet amyloidosis by the hormone IAPP, the production of advanced glycation endproducts (AGE), and insulin misprocessing into cytotoxic aggregates are all sources of β-cell proteotoxicity in diabetes.
|
29664151 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IAPP amyloid oligomers are biomarkers of the onset and progression of diabetes and could play a role as therapeutic targets.
|
28912603 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This short review provides a brief introduction to amylin biology, the use of an amylin analog to treat diabetes, and consideration of whether amylin could have any role in headache disorders.
|
28485843 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, the molecular basis of the huge metabolic benefits in bariatric surgery is emerging while novel incretin-based medicines based on endogenous hormones such as glucagon-like peptide 1 and pancreas-derived amylin are improving diabetes management.
|
28275047 |
2017 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Determine whether plasma levels of precursor forms of IAPP are elevated in diabetes.
|
28368485 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro, and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice.
|
27865831 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans.
|
28503657 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We generated an islet transplant model wherein immune-deficient mouse models of diabetes received islets expressing amyloidogenic human proIAPP and lacking PC2, leading to restoration of normoglycaemia accompanied by increased secretion of human proIAPP.
|
27999871 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further testing revealed islet-type amyloid polypeptide (or amylin), a protein found in various diseases such as diabetes, insulinoma and pancreatic adenocarcinoma-none of which was seen in our patient.
|
28739611 |
2017 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mice hemizygous for transgenic expression of human IAPP did not develop diabetes; however, loss of β cell-specific autophagy in these animals induced diabetes, which was attributable to accumulation of toxic human IAPP oligomers and loss of β cell mass.
|
25036708 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analogs of IAPP have been approved for the treatment of diabetes and are under investigation for the treatment of obesity.
|
23337872 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Islet amyloid polypeptide and diabetes.
|
23745697 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intriguingly, amylin deposition was also detected in blood vessels and brain parenchyma of patients with late onset AD without clinically apparent diabetes.
|
23794448 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice.
|
19794060 |
2010 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We transplanted a streptozotocin-induced mouse model of diabetes with 100 islets from human IAPP (which encodes islet amyloid polypeptide) transgenic mice that have the propensity to form islet amyloid (n = 8-12) or from non-transgenic mice that do not develop amyloid (n = 6-10) in sets of studies that lasted 1 or 6 weeks.
|
19002432 |
2009 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of fibrillogenic human amylin in these human amylin transgenic mice caused beta-cell degeneration and diabetes through mechanisms independent from both peripheral insulin resistance and islet amyloid.
|
18633116 |
2008 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that IAPP-induced beta-cell apoptosis causes defects in insulin secretion and beta-cell mass that lead first to hepatic insulin resistance and IFG and then to extrahepatic insulin resistance, hyperglucagonemia, and diabetes.
|
16804082 |
2006 |